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Abstract The impact of viral infection on normal host RNA
processing remains largely unexplored. We postulated that the
high abundance of virally derived nuclear RNA in infected cells
could impact host cell RNA splicing and viability. To test for
aberrant RNA splicing we examined trans-splicing following
infection with the replication-competent adenovirus mutant
d11520 that lacks E1B 55 kDa protein. Trans-splicing was
observed between viral RNA and several cellular precursor
mRNAs, including L-actin and glyceraldehyde-3-phosphate
dehydrogenase. Using a tetracycline-inducible model system
simulating viral trans-splicing activity we observed that over-
expression of a trans-splicing RNA specifically inhibited cell
proliferation. These results demonstrate that heterologous trans-
splicing occurs naturally during adenovirus infection and suggest
that trans-splicing may contribute to disruption of cell
function. ) 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
It is well established that the splicing of mRNA precursors
is an essential step in the maturation of almost all mRNAs in
higher organisms. For the most part this process occurs in cis,
splicing together exons within a single RNA precursor. How-
ever, recently several examples of naturally occurring trans-
splicing (the splicing of exons between two independently
transcribed pre-mRNAs) of mammalian pre-mRNAs have
been described [1^10]. It has been suggested that the creation
of intergenic mRNA molecules through trans-splicing may
represent an important mechanism for the creation of genetic
diversity and that the process is highly regulated [11]. This
ability of two independently transcribed RNA precursors to
‘trans-splice’ and form a unique mRNA product also has led
to the proposal that this machinery could be usurped to per-
form therapeutic gene correction at the RNA level. Indeed,
studies by Puttaraju et al. [12] found that overexpression of a
precursor trans-splicing molecule (PTM) that contained an
RNA targeting sequence, an unpaired 3P splice site (3P ss)
and the corrected gene sequence, could be used therapeutically
to modify speci¢c mutant RNAs. This approach has since
been used both in vitro and in vivo to successfully repair
mutant CFTR, Collagen 17A1 and h-ras mRNAs [13^16].
We used this approach in an attempt to correct mutations
in mutant RET proto-oncogene RNA precursors, but those
experiments had an unexpected result [17]. Overexpression of
an RNA containing a single exon with an unpaired adenovi-
rus 3P ss resulted in widespread non-targeted trans-splicing
and decreased cell viability [17]. This ¢nding led us to ponder
whether non-speci¢c trans-splicing was unique to this partic-
ular experimental model or perhaps was a natural occurrence
during the course of viral infection that might play a signi¢-
cant biological role.
The exact process by which adenovirus infection ultimately
mediates cell death following infection remains unclear. The
discovery of programmed cell death (apoptosis) and the in-
volvement of numerous adenoviral proteins in this process
have led to a renewed interest in the mechanisms involved
in adenoviral-mediated cell death. There appear to be at least
four adenoviral proteins involved in host cell death, E1a pro-
tein, E4ORF4, E4ORF6/7 and the adenoviral death protein
(ADP) (reviewed in [18]). The E1a and E4 proteins induce cell
death through the utilization of the p53-dependent and -inde-
pendent apoptotic pathways, though the precise mode of ac-
tion is unclear. For E4ORF4, recent studies have also shown
that in addition to regulation of gene expression at the tran-
scriptional level, E4ORF4 has the ability to modulate alter-
native RNA splicing [19]. E4ORF4 interacts speci¢cally with a
subset of the SR proteins, SF2/ASF and SRp30c, but not with
SRp20, SC35, SRp40, SRp55 or SRp75. This interaction ren-
ders these splicing factors inactive, has a demonstrated impact
on adenovirus RNA splicing, and is likely to a¡ect host RNA
splicing. Whether E4ORF4 a¡ects trans-RNA splicing is un-
known. The ADP gene product is an integral membrane pro-
tein that is required for e⁄cient host cell lysis. While these
viral proteins clearly play critical roles in viral-mediated cell
death, other epigenetic phenomena are thought to play essen-
tial roles. For example, it has been proposed that adenovirus
selectively promotes the export of viral RNAs from the nu-
cleus, blocking the transport of normal cellular mRNAs to the
cytoplasm, ultimately preventing translation of key proteins
required for cell viability [20]. Our results led us to consider
an additional mechanism that might contribute to viral-medi-
ated cell death.
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The replicative phase of viral infection parallels somewhat
what is observed following transfection of an expression plas-
mid. In both situations, there is excessive RNA accumulation
in the nucleus. Hypothetically, the presence of excessive nu-
clear viral precursor transcripts could lead to trans-splicing
between viral RNAs and cellular RNA precursors. Although
trans-splicing is believed to be strictly regulated, transfection
of an expression plasmid or viral infection may overwhelm the
normal regulatory mechanisms [2^11]. The result would be the
production of a variety of non-speci¢c chimeric trans-spliced
RNA products that could either directly or indirectly impact
cellular function su⁄ciently to cause cell death. In this study,
we examined if trans-splicing occurred between viral and host
mRNA precursors during infection and what role this aber-
rant trans-splicing might play in adenovirus-mediated cell
death.
2. Materials and methods
2.1. Cell lines and constructs
U251MG cells, which harbor a mutant allele of p53, were cultured
in Dulbecco’s modi¢ed Eagle’s medium (DMEM)/F12 (1:1, v/v) with
10% fetal bovine serum (FBS). JEG-3 cells were cultured in MEM
with 10% FBS. NIH 3T3 cells were cultured in DMEM with 10%
FBS. Construction of PTM plasmids is described elsewhere [17].
pTRE-myc/his and pTRE-3P ss myc/his were created by insertion of
the BamHI/PvuII fragment of pTMv3Pss and pTM into the corre-
sponding sites of pTRE (Clontech Laboratories, Palo Alto, CA,
USA). Development of the tetracycline-inducible system in NIH
3T3 cells was carried out according to protocols provided by manu-
facturer.
2.2. Adenovirus and infection
The dl1520 is a human group C adenovirus, serotype 5 and is
described elsewhere [21]. The construct used in this study is a generous
gift of Dr. R. Alemany and Dr. Curiel, Unit of Gene Therapy, Uni-
versity of Alabama at Birmingham, AL, USA. U251MG cells were
plated on a 10-cm culture dish prior to infection. The cells were in-
fected using 100 MOI of Ad dl1520, which is replication-competent in
p53 mutant cell lines as reported previously [22].
2.3. Transfection
Transfection was carried out using Gene Porter 2 reagent (Gene
Therapy Systems, San Diego, CA, USA) according to protocols pro-
vided by the manufacturer.
2.4. RT-PCR and sequencing
Reverse transcription was performed using mRNA capture kit
(Roche Diagnostics, Indianapolis, IN, USA) according to protocols
provided by the manufacturer. A touchdown program was employed
for the ¢rst round PCR. Following the initial 3 min denaturing step at
94‡C, three steps consisting of 15 s for denaturing at 94‡C, 30 s for
annealing and 1 min for elongation at 72‡C were repeated for 10 times.
Annealing temperature began with 68‡C and decreased 1‡ for each
cycle. Following the touchdown phase, conventional 30-cycle PCR
(15 s at 94‡C, 20 s at 57‡C, 1 min at 72‡C) was carried out. For
semi-nested PCR, 2 Wl of 1/10-diluted ¢rst round PCR product was
added to second PCR. PCR products (15 Wl) were electrophoresed on
8% TBE polyacrylamide gels and visualized by ethidium bromide
staining. Sequencing of spliced products is described elsewhere [17].
2.5. 5P RACE
Identi¢cation of chimeric RNAs was carried out using the 5P RACE
system (rapid ampli¢cation of cDNA ends), version 2.0 (Life Tech-
nologies) according to the manufacturer’s protocol with minor mod-
i¢cations. In brief, 5 Wg of total RNA was annealed with biotin-con-
jugated oligo-(dT)20 primer (5 pmol) in lysis bu¡er for mRNA capture
kit and puri¢ed using streptavidin-coated PCR tube (Roche) (as
above for RT-PCR). The cDNA synthesis and homopolymeric tailing
was performed according to the protocol provided by the manufac-
turer. The tailed cDNAs were then ampli¢ed using the abridged an-
chor primer (Life Technologies) and Ad ex2-R1 primer. The ¢rst
round PCR product was then ampli¢ed using nested primers
(AUAP (Life technologies) and Ad ex2-R3). Prior to the second
PCR step, products were digested with PvuII, which is located in
the major late transcript (MLT) leader exon 1, to reduce intrinsic
adenoviral MLT mRNA-derived products. Following the second
PCR step, PCR products were puri¢ed using the High Pure PCR
Product Puri¢cation kit (Roche) and ¢nally cloned into pGEM-Teasy
plasmid (Promega). DNA sequencing used the Minx-R primer.
2.6. Metabolic labeling and immunoprecipitation
For detection of myc/his-tagged cellular proteins, NIH 3T3
(0.25U106 cells/well on a six-well plate) cells were transfected with
pTM or pTMv3Pss or pVP22/myc-His. Transfected cells were meta-
bolically labeled with [35S]methionine (25 WCi/well) for 4 h. The la-
beled cells were washed and lysed in RIPA bu¡er containing 2 mM
EDTA, 1 Wg/ml pepstatin, and 1 mM phenylmethylsulfonyl £uoride.
The supernatant was cleared by incubation with protein G-Sepharose
(Amersham Pharmacia Biotech, Arlington Heights, IL, USA).
Cleared lysate was incubated with 1.5 Wl of anti-myc (Invitrogen,
Carlsbad, CA, USA), 5 Wl of anti-actin (Santa Cruz, Santa Cruz,
CA, USA) antibodies and 15 Wl protein G-Sepharose in 500 Wl
NET-gel bu¡er (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Nonidet
P-40, 1 mM EDTA, 0.25% gelatin, and 0.02% NaN3) overnight at
4‡C. Following two washes with Nonidet P-40 lysis bu¡er (50 mM
Tris, pH 8.0, 150 mM NaCl, 0.1% Nonidet P-40), the pelleted anti-
body^antigen complex was denatured and analyzed in 16% SDS^
PAGE. Radioactivity of each lane was estimated using NIH image
software (ver. 1.62).
2.7. Cell proliferation assay
Ten thousand cells from each clone line (pTet-On pTRE myc/his or
pTet-On pTRE 3P ss myc/his) were plated into a 24-well tissue culture
plate the day before addition of doxycycline (2 Wg/ml) (day 0). The
medium was replenished every 2 days. Cell number was counted using
a hemocytometer. The experiment was performed in quadruplicate.
Colorimetric assay (WST-1 assay system, Roche) yielded similar re-
sults.
2.8. Primers
Ad ex2-R1, TTCGGAGGCCGACGGGTTTC; Ad ex2-R3, CC-
GATCCAAGAGTACTGGAA; BGHrev, ACTAGAAGGCACA-
GTCGAGGCT; Hisrev, CAATGGTGATGGTGATGATGAC; GA-
PDH-F1, AGTGGATATTGTTGCCATCA; GAPDH-F2, GACCC-
CTTCATTGACCTC; L-actin-F1, CAACTGGGACGACATGGA;
L-actin-F2, TCTGGCACCACACCTTCTAC; Minx-R, TGGAAAG-
ACCGCGAAGAG.
3. Results and discussion
We have previously observed that overexpression of an un-
paired adenovirus 3P ss derived from exon 2 of the MLT
resulted in widespread non-targeted trans-splicing with other
RNA precursors [17]. This ¢nding led us to question whether
the same 3P ss within the intact naturally occurring adenovirus
would also be capable of trans-splicing during adenoviral in-
fection. To address this question we used the well-character-
ized replication-competent adenovirus strain Ad dl1520
[22,23]. This speci¢c virus has been widely employed as an
oncolytic agent because it is only capable of lytic replication
in p53-de¢cient cell lines due to the lack of E1B-55 protein
[22]. Total RNA was isolated during productive infection (48 h
post infection) to determine whether targeted trans-splicing
could be detected between two common genes (glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) and L-actin)
and the adenovirus type 5 MLT leader exon 2. An initial
RT-PCR reaction was performed using exon-speci¢c primers
followed by 30 cycles of semi-nested PCR in order to reduce
RT-PCR background (Fig. 1A). Very little product was ob-
served after the ¢rst round of RT-PCR suggesting that trans-
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splicing products did not exist at high abundance (Fig. 1B).
However, following the second semi-nested PCR we were able
to detect several RT-PCR bands that correspond to predicted
trans-splicing products (multiple introns of the GAPDH gene
were involved). The presence of these bands was dependent on
viral infection and not observed in mock-infected cells (Fig.
1B). Sequencing of the product bands con¢rmed accurate use
of existing splice sites, suggesting that these products were
generated through a trans-splicing mechanism (Fig. 1C). In-
tegration of adenovirus into the host genome, another mech-
anism for producing the observed products, has not been
reported for productive viral infection although a few exam-
ples have been described for non-productive infection [24,25].
To exclude this possibility, we performed PCR using genomic
DNA from the virally infected cells. No PCR products were
detected, con¢rming our contention that these RNAs were
generated through a trans-splicing mechanism (data not
shown).
This ¢nding was unexpected and raised several important
questions. The ¢rst was ‘How widespread is this phenome-
non?’ Our initial study only examined trans-splicing between
a single adenovirus exon and two speci¢c genes. To explore
the extent to which cellular pre-mRNA is captured by adeno-
virus pre-mRNA through a trans-splicing mechanism, we per-
formed 5P RACE with RNA from the infected cells using
downstream primers located in the MLT leader exon 2. To
reduce the presence of MLT cis-spliced products the 5P RACE
cDNA was digested with PvuII following the ¢rst round of
PCR. This enzyme restricts a site located in the adenovirus
MLT exon 1. Sequencing of 10 clones indicated that a broad
spectrum of cellular pre-mRNAs undergo trans-splicing dur-
ing productive infection (Fig. 2). Two common features of
sequenced products were observed: trans-splicing occurred
in a large intron (most are s 20 kb); and splicing occurred
in the ¢rst intron or in an intron close to the 5P end of the pre-
mRNA. The former implies that genes with large introns may
be more susceptible to trans-splicing. The latter feature may
be attributed to technical restriction of 5P RACE (where
shorter products are preferably ampli¢ed).
While our 5P RACE experiment gave some idea of the di-
versity of precursor mRNAs subject to trans-splicing, it did
not address the overall importance of trans-spliced transcripts
generated by adenoviral infection. None of the chimeric gene
transcripts identi¢ed seem to be targets that would be critical
to cellular proliferation. To show trans-splicing is an impor-
tant process in this context, we developed a construct to test
Fig. 1. Trans-splicing is associated with adenovirus infection. A: Structure of GAPDH, L-actin and adenovirus type 5 MLT precursor mRNAs
showing the relative position of the primers used for ampli¢cation of trans-spliced products (¢gure is not to scale). B: RT-PCR of RNA from
the cells infected with adenovirus. Roman numerals indicate presumed chimeric products schematically represented. A, adenovirus-infected cells;
M, mock-infected cells; 1st, ¢rst round PCR; 2nd, semi-nested PCR. MW, 100-bp DNA ladder. C: Direct sequencing of trans-spliced products.
Arrows indicate the splice junctions between GAPDH or L-actin exons and adenovirus MLT leader exon 2. Roman numerals correspond to
those in panel B.
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the hypothesis that trans-splicing alters cellular functions. A
PTM was generated using the 3P ss sequence of adenovirus
type 5 MLT intron 1 followed by human c-myc epitope (30
nt), polyhistidine molecular tag (18 nt) (myc/his) and bovine
growth hormone polyadenylation signal (Fig. 3A) [17]. This
construct can only produce a translatable mRNA by trans-
splicing. A control vector in which the 3P ss was removed was
also generated (pTMv3Pss). The PTM was transfected into
JEG-3 (human choriocarcinoma cell line) by lipofection.
This experiment showed trans-splicing between the GAPDH
and L-actin, analogous to that seen for adenovirus infection
(compare Figs. 1B and 3B). The authenticity of these chimeric
transcripts was veri¢ed by direct sequencing of PCR products
(data not shown). These chimeric transcripts were considered
to be generated through trans-splicing since no equivalent
products were detected from genomic DNA of the transfected
cells and transfection of pTMv3Pss generated no equivalent
products (data not shown).
To provide some estimate of the extent to which cellular
mRNA undergoes trans-splicing, we used the human c-myc
epitope to immunoprecipitate chimeric proteins (using an
anti-human c-myc antibody). Use of a mouse cell line (NIH
3T3) avoided cross-reaction and immunoprecipitation of en-
dogenous c-myc. Cells were transfected with pTMv3Pss, pTM
or pVP22/myc-His (Invitrogen) which generates myc/his-
tagged VP22 protein (45 kDa) as a positive control for the
anti-myc antibody. Following transfection, cells were metabol-
ically labeled with [35S]methionine to examine new protein
synthesis. Immunoprecipitation using anti-myc and anti-actin
(for an internal control) antibodies is shown in Fig. 4A. The
lysate of the cells transfected with pVP22/myc-His clearly
demonstrated the presence of myc/his-tagged VP22 protein.
A comparison of precipitable protein observed in cells trans-
fected with pTMv3Pss versus pTM demonstrated the emer-
gence of innumerable c-myc-tagged protein bands, considered
to be chimeric proteins generated from trans-splicing of cellu-
lar pre-mRNA and the PTM. The overall level of tagged
proteins detected was three-fold greater than observed in con-
trol cells, which is even more striking when one considers that
only trans-splicing events that provide an in-frame start codon
can be detected.
The balanced spectrum of protein sizes observed in the im-
munoprecipitation experiment and the range of RACE prod-
ucts cloned during adenoviral infection suggest that trans-
splicing mediated from this adenovirus splice site is non-spe-
ci¢c and prevalent, though this does not rule out the possi-
bility that speci¢c regulatory chimeric RNAs are produced.
This raises the obvious question of whether unregulated
trans-splicing might be deleterious to normal cellular function.
That this was the case was demonstrated in two ways. First,
we attempted to create stable clones from PTM-transfected
cells and were unsuccessful despite several attempts, whereas
stable clones were readily developed from the control vector
(pTMv3Pss). This result suggests that the disadvantageous ef-
fects of PTM expression eliminate clones under selection pres-
sure. Second, since expression of PTM is presumed to be
Fig. 2. A broad spectrum of cellular genes undergo trans-splicing. The sequencing of several clones derived by 5P RACE is shown. Arrowheads
indicate the splice junction between the last nucleotide of a cellular exon involved and the ¢rst nucleotide of adenovirus MLT leader exon 2.
The identities of trans-spliced genes are indicated at the bottom of the ¢gure.
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detrimental to cell viability, we created stable clones capable
of tetracycline-inducible expression of PTM (pTRE-3P ss myc/
his) or control RNA (pTRE myc/his). The constructs used to
create these clones are identical to the plasmids shown in Fig.
3A except that the CMV promoter has been replaced with a
tetracycline-responsive promoter (TRE). Expression of the
myc/his or 3P ss myc/his sequence was up-regulated by the
addition of doxycycline (Fig. 4B, inset). Furthermore, induc-
tion of the PTM by doxycycline was capable of a modest, but
signi¢cant inhibition cell growth, whereas no e¡ect on growth
was observed for the control cells (Fig. 4).
Our ¢ndings indicate clearly that trans-splicing between cel-
lular host pre-mRNAs and adenovirus pre-mRNA occurs
during the natural course of infection. This trans-splicing is
promiscuous and occurs at multiple splice sites within a given
gene transcript. To the best of our knowledge, this is the ¢rst
example of naturally occurring heterologous trans-splicing be-
tween viral and cellular host RNA transcripts. Our ¢nding is
not entirely unexpected given that the arti¢cial overexpression
of foreign RNA precursors by transfection has clearly been
demonstrated to cause trans-splicing [12^17]. Indeed, recent
studies by Caudevilla et al. [26] have shown that plasmids
encoding the HIV-nef viral transcript when expressed in
CV-1 cells is capable of trans-splicing with host cell RNA
precursors, lending support to the idea that trans-splicing oc-
curs naturally during viral infection. However, in this report it
was the viral RNA transcript that was targeted by trans-splic-
ing mediated through the 3P ss of host cell precursor RNAs.
What is unclear is whether the targeted HIV-nef 5P splice sites
and the 3P ss sequence of adenovirus type 5 MLT intron 1
represent unique cases where these splice sites are more prone
to trans-splicing. For the carnitine octanoyltransferase gene, a
speci¢c purine-rich exonic enhancer (GAAGAAG) is respon-
sible for promotion of trans-splicing [27]. Similar purine-rich
sequences exist throughout the adenovirus genome including
MLT exon 2, however we have no experimental evidence to
suggest that these sequences function to enhance trans-splicing
of adenoviral transcripts with host cell RNAs. In addition, the
e¡ects of E4ORF4 to inhibit SR protein activity, which are
mediators of many splicing enhancer actions, at least argues
against an SF2/ASF- or SRp30-mediated enhancement of
trans-splicing [19].
Fig. 3. A PTM simulates the trans-splicing activity of adenovirus.
A: Schematic representation of vectors used (CMV, cytomegalovirus
immediate early promoter and enhancer; BGHpA, bovine growth
hormone polyadenylation signal). B: RT-PCR of RNA from JEG-3
cells transfected with pTM expression vector. Roman numerals indi-
cate presumed chimeric products schematically represented.
Fig. 4. Trans-splicing to cellular RNA creates a spectrum of protein products and alters cell proliferation. A: Transfection of pTM induced the
generation of chimeric protein products detectable by anti-c-myc immunoprecipitation. The plasmids used for transfection are indicated at the
top of each lane. Relative counts for the entire lane are shown. B: Cell proliferation of NIH 3T3 clones in which expression of pTM is induc-
ible by addition of doxycycline (tetracycline-derivative). *P6 0.05; **P6 0.01 against uninduced control. Inset, induced expression of myc/his
or 3P ss myc/his sequence with doxycycline. RNA from the cells of each clone was subjected to RT-PCR using expression unit-speci¢c primers
(25 cycles).
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In addition, we have demonstrated that trans-splicing be-
tween abundantly expressed vector-derived RNAs and endog-
enous pre-mRNA inhibits cell growth. While these ¢ndings
are provocative because they suggest a potential epigenetic
mechanism whereby aberrant trans-RNA splicing may disrupt
cell proliferation, they do not address if trans-splicing plays a
speci¢c role in adenoviral-mediated host cell death. However,
we perceive two potential mechanisms by which trans-splicing
could act to impact cell viability. In the ¢rst trans-splicing
could result in the production of a speci¢c and unique product
that profoundly a¡ects cell growth or death. For example,
targeted trans-splicing of any of several anti-apoptotic genes
would be predicted to enhance cell death. Alternatively, the
phenomena may be non-speci¢c. In this case, the broad-based
disruption of cis-splicing would be expected to cause a de-
creased production of critical cellular proteins responsible
for host cell growth. That either mechanism could play a
distinct role in adenovirus-mediated disruption of cellular
function provides an intriguing area for additional investiga-
tion.
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